ArticleMolecular biomedicine2026
Twist Family BHLH Transcription Factor 1 orchestrates hypoxia-lactate crosstalk to bridge glycolytic flux and tubular maladaptation in fibrotic kidneys.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The reprogramming of glycolytic metabolism is essential for maintaining the reparative homeostasis of tubular epithelial cells (TECs). Maladaptive TEC repair mechanisms drive the progression from acute kidney injury (AKI) to chronic kidney disease (CKD). Twist Family BHLH Transcription Factor 1 (Twist1) has been implicated in epithelial-mesenchymal transition and metabolic dysregulation in cancer and fibrotic diseases. Twist1 promotes renal fibrosis through lipid accumulation in TECs by transcriptionally regulating genes involved in lipid metabolism. The role of Twist1 in glycolytic reprogramming during the transition from AKI to CKD was investigated. Tubular Twist1 knockout mice, RNA sequencing, metabolomics, and in vivo and in vitro experiments were used to evaluate the function and mechanism of Twist1-regulated glycolytic reprogramming. Twist1 orchestrated a dual metabolic insult of fatty acid oxidation suppression and glycolysis hyper-activation, thereby rewiring TEC processes toward a pro-fibrotic phenotype. Hypoxia-induced Twist1 activated hexokinase-2-driven glycolysis and amplified lactate accumulation, thereby stabilizing Twist1 expression through epigenetic modifications. Multidimensional studies demonstrated that lactate significantly enhanced maladaptive repair processes in TECs and contributed to renal fibrosis through a positive feedback loop that exacerbated glycolysis. Mechanistically, lactylation of histone H3 at K18 (H3K18lac) upregulated Twist1 transcription, which in turn accelerated hexokinase-2 expression and further promoted glycolytic activity. This study elucidates a lactate/H3K18lac/Twist1/hexokinase-2 axis as a central mechanism driving AKI-to-CKD progression. Twist1 emerges as a hypoxia-responsive transcription factor that amplifies glycolysis in a self-reinforcing cycle that fuels fibrosis. This study uniquely positions Twist1 as a hypoxia-responsive transcription factor in renal fibrosis and implicates lactate in autocrine TEC reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.